141P Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study

Transurethral resection of bladder tumor (TURBT) combined with concurrent chemoradiotherapy is the standard treatment for bladder preservation in MIBC. TURBT alone and partial cystectomy are only suitable for selected patients with solitary tumors, T2, and tumors in the bladder diverticulum. One of the major concerns is the possibility of residual tumor and the increasing risk of metastasis after surgery. Systemic treatment after radical TURBT or partial cystectomy may prevent recurrence and metastasis.